Skip to main content
main-content
Erschienen in: Die Urologie 7/2009

01.07.2009 | Leitthema

Immunmodulatorische Therapieansätze beim Prostatakarzinom

verfasst von: M.A. Reiter, J. Pfitzenmaier, M. Hohenfellner, PD Dr. A. Haferkamp

Erschienen in: Die Urologie | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Während der letzten 10 Jahre wurden verschiedene Ansätze zur Immuntherapie beim Prostatakarzinom untersucht. Dazu gehören unspezifische sowie spezifische immunstimulierende bzw. immunmodulierende Therapien. Bei der unspezifischen Immuntherapie des Prostatakarzinoms werden humorale und zelluläre Reaktionsmechanismen des Immunsystems antigenunspezifisch moduliert oder stimuliert. Ziel ist die Auslösung einer Entzündungsreaktion oder eines anderen bereits bestehenden Abwehrmechanismus zur Bekämpfung des Malignoms. Die Mediatoren und Effektorzellen dieser unspezifischen Immunantwort sind humorale Faktoren wie Zytokine, Komplement und Akutphaseproteine sowie zelluläre Komponenten des Immunsystems, wie Neutrophile, Makrophagen/Monozyten, Mastzellen und Natural-Killer-Zellen.
Im Gegensatz dazu ist es das Ziel der spezifischen Immuntherapie, zelluläre und humorale Immuneffektormechanismen zur zielgerichteten Erkennung und Zerstörung von Tumorzellen zu aktivieren. Die erfolgversprechendsten Ansätze der spezifischen Immuntherapie sind dabei Vakzinierungsstrategien mit Generierung einer antitumoralen T-Zell-Antwort und die Verabreichung von Antikörpern.
In Rahmen einer PubMed-basierten Literaturrecherche wurden Publikationen zur immunmodulatorischen Therapie des Prostatakarzinoms identifiziert. Der vorliegende Artikel fokussiert auf die zum Zeitpunkt der Publikation vorliegenden klinischen Studien zu immunmodulatorischen Therapieoptionen beim Prostatakarzinom und stellt deren bisherige Ergebnisse dar.
Literatur
1.
Zurück zum Zitat Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3): 581–592 PubMedCrossRef Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3): 581–592 PubMedCrossRef
2.
3.
Zurück zum Zitat Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17): 1591–1597 PubMedCrossRef Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17): 1591–1597 PubMedCrossRef
4.
Zurück zum Zitat Maximum androgen blockade in advanced prostate cancer (1995) an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists Collaborative Group. Lancet 346(8970): 265–269 Maximum androgen blockade in advanced prostate cancer (1995) an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists Collaborative Group. Lancet 346(8970): 265–269
5.
Zurück zum Zitat Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513–1520 PubMedCrossRef Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513–1520 PubMedCrossRef
6.
Zurück zum Zitat Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502–1512 PubMedCrossRef Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502–1512 PubMedCrossRef
7.
Zurück zum Zitat Pollard M, Luckert PH (1993) The anti-metastatic effect of intravenously-inoculated BCG on prostate tumor cells. Anticancer Res 13(3): 705–708 PubMed Pollard M, Luckert PH (1993) The anti-metastatic effect of intravenously-inoculated BCG on prostate tumor cells. Anticancer Res 13(3): 705–708 PubMed
8.
Zurück zum Zitat Pollard M, Luckert PH (1994) The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats. Anticancer Res 14(3A): 901–903 PubMed Pollard M, Luckert PH (1994) The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats. Anticancer Res 14(3A): 901–903 PubMed
9.
Zurück zum Zitat Guinan P, Toronchi E, Shaw M et al (1982) Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 20(4): 401–403 PubMedCrossRef Guinan P, Toronchi E, Shaw M et al (1982) Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 20(4): 401–403 PubMedCrossRef
10.
Zurück zum Zitat Guinan PD, John T, Nagale V, Ablin RJ (1978) BCG adjuvant immunotherapy in carcinoma of the prostate: an interim report. Allergol Immunopathol (Madr) 6(4): 293–296 Guinan PD, John T, Nagale V, Ablin RJ (1978) BCG adjuvant immunotherapy in carcinoma of the prostate: an interim report. Allergol Immunopathol (Madr) 6(4): 293–296
11.
Zurück zum Zitat Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1977) Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate. Br J Urol 49(3): 221–226 PubMedCrossRef Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1977) Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate. Br J Urol 49(3): 221–226 PubMedCrossRef
12.
Zurück zum Zitat Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1978) Prostate carcinoma: intratumor BCG immunotherapy. J Natl Cancer Inst Monogr 49: 351–353 Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1978) Prostate carcinoma: intratumor BCG immunotherapy. J Natl Cancer Inst Monogr 49: 351–353
13.
Zurück zum Zitat Hrouda D, Souberbielle BE, Kayaga J et al (1998) Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 82(6): 870–876 PubMed Hrouda D, Souberbielle BE, Kayaga J et al (1998) Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 82(6): 870–876 PubMed
14.
Zurück zum Zitat Hrouda D, Baban B, Dunsmuir WD et al (1998) Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 82(4): 568–573 PubMed Hrouda D, Baban B, Dunsmuir WD et al (1998) Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 82(4): 568–573 PubMed
15.
Zurück zum Zitat Krejci KG, Markiewicz MA, Kwon ED (2004) Immunotherapy for urological malignancies. J Urol 171(2 Pt 1): 870–876 PubMedCrossRef Krejci KG, Markiewicz MA, Kwon ED (2004) Immunotherapy for urological malignancies. J Urol 171(2 Pt 1): 870–876 PubMedCrossRef
16.
Zurück zum Zitat Heinzer H, Huland E, Huland H (2001) Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 19(2): 111–119 PubMedCrossRef Heinzer H, Huland E, Huland H (2001) Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 19(2): 111–119 PubMedCrossRef
17.
Zurück zum Zitat Hautmann SH, Huland E, Huland H (1999) Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res 19(4A): 2661–2663 PubMed Hautmann SH, Huland E, Huland H (1999) Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res 19(4A): 2661–2663 PubMed
18.
Zurück zum Zitat Kocheril SV, Grignon DJ, Wang CY et al (1999) Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. Cancer Detect Prev 23(5): 408–416 PubMedCrossRef Kocheril SV, Grignon DJ, Wang CY et al (1999) Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. Cancer Detect Prev 23(5): 408–416 PubMedCrossRef
19.
Zurück zum Zitat Dieli F, Vermijlen D, Fulfaro F et al (2007) Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15): 7450–7457 PubMedCrossRef Dieli F, Vermijlen D, Fulfaro F et al (2007) Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15): 7450–7457 PubMedCrossRef
20.
Zurück zum Zitat Maffezzini M, Simonato A, Fortis C (1996) Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 28(5): 282–286 PubMedCrossRef Maffezzini M, Simonato A, Fortis C (1996) Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 28(5): 282–286 PubMedCrossRef
21.
Zurück zum Zitat Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90(8): 3539–3543 PubMedCrossRef Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90(8): 3539–3543 PubMedCrossRef
22.
Zurück zum Zitat Dreicer R, See WA, Klein EA (2001) Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs 19(3): 261–265 PubMedCrossRef Dreicer R, See WA, Klein EA (2001) Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs 19(3): 261–265 PubMedCrossRef
23.
Zurück zum Zitat Small EJ, Reese DM, Um B et al (1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5(7): 1738–1744 PubMed Small EJ, Reese DM, Um B et al (1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5(7): 1738–1744 PubMed
24.
Zurück zum Zitat Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21(1): 99–105 PubMedCrossRef Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21(1): 99–105 PubMedCrossRef
25.
Zurück zum Zitat Rini BI, Fong L, Weinberg V et al (2006) Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175(6): 2087–2091 PubMedCrossRef Rini BI, Fong L, Weinberg V et al (2006) Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175(6): 2087–2091 PubMedCrossRef
26.
Zurück zum Zitat Ryan CJ, Weinberg V, Rosenberg J et al (2007) Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol 178(6): 2372–2376 PubMedCrossRef Ryan CJ, Weinberg V, Rosenberg J et al (2007) Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol 178(6): 2372–2376 PubMedCrossRef
27.
Zurück zum Zitat Dreicer R, Klein EA, Elson P et al (2005) Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 23(2): 82–86 PubMed Dreicer R, Klein EA, Elson P et al (2005) Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 23(2): 82–86 PubMed
28.
Zurück zum Zitat Kramer G, Steiner GE, Sokol P et al (2001) Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res 21(7): 475–484 PubMedCrossRef Kramer G, Steiner GE, Sokol P et al (2001) Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res 21(7): 475–484 PubMedCrossRef
29.
Zurück zum Zitat Kiessling A, Fussel S, Wehner R et al (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53(4): 694–708 PubMedCrossRef Kiessling A, Fussel S, Wehner R et al (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53(4): 694–708 PubMedCrossRef
30.
Zurück zum Zitat Noguchi M, Itoh K, Yao A et al (2005) Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 63(1): 1–12 PubMedCrossRef Noguchi M, Itoh K, Yao A et al (2005) Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 63(1): 1–12 PubMedCrossRef
31.
Zurück zum Zitat Gates JD, Carmichael MG, Benavides LC et al (2009) Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg 208(2): 193–201 PubMedCrossRef Gates JD, Carmichael MG, Benavides LC et al (2009) Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg 208(2): 193–201 PubMedCrossRef
32.
Zurück zum Zitat Eder JP, Kantoff PW, Roper K et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6(5): 1632–1638 PubMed Eder JP, Kantoff PW, Roper K et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6(5): 1632–1638 PubMed
33.
Zurück zum Zitat Gulley J, Chen AP, Dahut W et al (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2): 109–117 PubMedCrossRef Gulley J, Chen AP, Dahut W et al (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2): 109–117 PubMedCrossRef
34.
Zurück zum Zitat Kaufman HL, Wang W, Manola J et al (2004) Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22(11): 2122–2132 PubMedCrossRef Kaufman HL, Wang W, Manola J et al (2004) Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22(11): 2122–2132 PubMedCrossRef
35.
Zurück zum Zitat Arlen PM, Gulley JL, Parker C et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4): 1260–1269 PubMedCrossRef Arlen PM, Gulley JL, Parker C et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4): 1260–1269 PubMedCrossRef
36.
Zurück zum Zitat Amato RJ, Drury N, Naylor S et al (2008) Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 31(6): 577–585 PubMedCrossRef Amato RJ, Drury N, Naylor S et al (2008) Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 31(6): 577–585 PubMedCrossRef
37.
Zurück zum Zitat Madan RA, Gulley JL, Schlom J et al (2008) Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide and combination therapy. Clin Cancer Res 14(14): 4526–4531 PubMedCrossRef Madan RA, Gulley JL, Schlom J et al (2008) Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide and combination therapy. Clin Cancer Res 14(14): 4526–4531 PubMedCrossRef
38.
Zurück zum Zitat Pavlenko M, Roos AK, Lundqvist A et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91(4): 688–694 PubMed Pavlenko M, Roos AK, Lundqvist A et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91(4): 688–694 PubMed
39.
Zurück zum Zitat Simons JW, Carducci MA, Mikhak B et al (2006) Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 12(11 Pt 1): 3394–3401 PubMedCrossRef Simons JW, Carducci MA, Mikhak B et al (2006) Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 12(11 Pt 1): 3394–3401 PubMedCrossRef
40.
Zurück zum Zitat Urba WJ, Nemunaitis J, Marshall F et al (2008) Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 180(5): 2011–2017 PubMedCrossRef Urba WJ, Nemunaitis J, Marshall F et al (2008) Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 180(5): 2011–2017 PubMedCrossRef
41.
Zurück zum Zitat Small EJ, Sacks N, Nemunaitis J et al (2007) Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13(13): 3883–3891 PubMedCrossRef Small EJ, Sacks N, Nemunaitis J et al (2007) Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13(13): 3883–3891 PubMedCrossRef
42.
Zurück zum Zitat Higano CS, Corman JM, Smith DC et al (2008) Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5): 975–984 PubMedCrossRef Higano CS, Corman JM, Smith DC et al (2008) Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5): 975–984 PubMedCrossRef
43.
Zurück zum Zitat Steinman RM (2003) Some interfaces of dendritic cell biology. Apmis 111(7–8): 675–697 Steinman RM (2003) Some interfaces of dendritic cell biology. Apmis 111(7–8): 675–697
44.
Zurück zum Zitat Hsu FJ, Benike C, Fagnoni F et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2(1): 52–58 PubMedCrossRef Hsu FJ, Benike C, Fagnoni F et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2(1): 52–58 PubMedCrossRef
45.
Zurück zum Zitat Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3): 328–332 PubMedCrossRef Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3): 328–332 PubMedCrossRef
46.
Zurück zum Zitat Murphy G, Tjoa B, Ragde H et al (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29(6): 371–380 PubMedCrossRef Murphy G, Tjoa B, Ragde H et al (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29(6): 371–380 PubMedCrossRef
47.
Zurück zum Zitat Tjoa BA, Erickson SJ, Bowes VA et al (1997) Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32(4): 272–278 PubMedCrossRef Tjoa BA, Erickson SJ, Bowes VA et al (1997) Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32(4): 272–278 PubMedCrossRef
48.
Zurück zum Zitat Tjoa BA, Simmons SJ, Bowes VA et al (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36(1): 39–44 PubMedCrossRef Tjoa BA, Simmons SJ, Bowes VA et al (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36(1): 39–44 PubMedCrossRef
49.
Zurück zum Zitat Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12): 1524–1533 PubMedCrossRef Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12): 1524–1533 PubMedCrossRef
50.
Zurück zum Zitat Barrou B, Benoit G, Ouldkaci M et al (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53(5): 453–460 PubMedCrossRef Barrou B, Benoit G, Ouldkaci M et al (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53(5): 453–460 PubMedCrossRef
51.
Zurück zum Zitat Heiser A, Coleman D, Dannull J et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3): 409–417 PubMed Heiser A, Coleman D, Dannull J et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3): 409–417 PubMed
52.
Zurück zum Zitat Su Z, Dannull J, Yang BK et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174(6): 3798–3807 PubMed Su Z, Dannull J, Yang BK et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174(6): 3798–3807 PubMed
53.
Zurück zum Zitat Small EJ, Fratesi P, Reese DM et al (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23): 3894–3903 PubMed Small EJ, Fratesi P, Reese DM et al (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23): 3894–3903 PubMed
54.
Zurück zum Zitat Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19): 3089–3094 PubMedCrossRef Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19): 3089–3094 PubMedCrossRef
55.
Zurück zum Zitat Milowsky MI, Nanus DM, Kostakoglu L et al (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22(13): 2522–2531 PubMedCrossRef Milowsky MI, Nanus DM, Kostakoglu L et al (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22(13): 2522–2531 PubMedCrossRef
56.
Zurück zum Zitat Bander NH, Milowsky MI, Nanus DM et al (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23(21): 4591–4601 PubMedCrossRef Bander NH, Milowsky MI, Nanus DM et al (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23(21): 4591–4601 PubMedCrossRef
57.
Zurück zum Zitat Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26(13): 2147–2154 PubMedCrossRef Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26(13): 2147–2154 PubMedCrossRef
58.
Zurück zum Zitat Lara PN Jr, Chee KG, Longmate J et al (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100(10): 2125–2131 PubMedCrossRef Lara PN Jr, Chee KG, Longmate J et al (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100(10): 2125–2131 PubMedCrossRef
59.
Zurück zum Zitat Slovin SF, Scher HI, Divgi CR et al (1998) Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 4(3): 643–651 PubMed Slovin SF, Scher HI, Divgi CR et al (1998) Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 4(3): 643–651 PubMed
60.
Zurück zum Zitat Di Lorenzo G, Figg WD, Fossa SD et al (2008) Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 54(5): 1089–1094 CrossRef Di Lorenzo G, Figg WD, Fossa SD et al (2008) Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 54(5): 1089–1094 CrossRef
61.
Zurück zum Zitat Fong L, Kwek SS, O’Brien S et al (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69(2): 609–615 PubMedCrossRef Fong L, Kwek SS, O’Brien S et al (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69(2): 609–615 PubMedCrossRef
62.
Zurück zum Zitat Emerson L, Morales A (2009) Intralesional recombinant alpha-interferon localised prostate cancer: a pilot study with follow-up of 10 years. BJU (epub ahead) Emerson L, Morales A (2009) Intralesional recombinant alpha-interferon localised prostate cancer: a pilot study with follow-up of 10 years. BJU (epub ahead)
Metadaten
Titel
Immunmodulatorische Therapieansätze beim Prostatakarzinom
verfasst von
M.A. Reiter
J. Pfitzenmaier
M. Hohenfellner
PD Dr. A. Haferkamp
Publikationsdatum
01.07.2009
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 7/2009
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-009-1984-6

Weitere Artikel der Ausgabe 7/2009

Die Urologie 7/2009 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Urologie und bleiben Sie gut informiert – ganz bequem per eMail.